Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche Launches GS FLX+ System Software Update

Published: Wednesday, August 07, 2013
Last Updated: Wednesday, August 07, 2013
Bookmark and Share
The latest software version 2.9 enables highly accurate sequencing of long 16S ribosomal RNA amplicons for more precise taxonomic assignment of organisms in microbial surveys.

Roche has announced the global launch of a new software update that significantly extends the range of amplicon lengths available for targeted next-generation sequencing studies on the 454 GS FLX+ System.

The latest software enables sequencing of amplicons up to 800 bp while maintaining >99% accuracy over the length of the read.

High quality sequencing of even longer amplicons up to 1,100 bp has been successfully demonstrated in early access testing.

The long read improvements allow researchers to obtain more complete coverage of target gene regions using fewer amplicons, both simplifying experimental design and improving the biological relevance of sequencing results.

“This is another step in our continued efforts to drive high quality, long read sequencing advancements for the genomics community,” said Frank Pitzer, President Roche Sequencing Solutions. “We are actively working to make these same long read developments available on our benchtop GS Junior System in 2014.”

Long amplicon read lengths are critical for a variety of targeted sequencing applications including human gene sequencing and viral drug resistance studies as well as microbial community analysis.

Early results of targeted sequencing of 16S and 18S ribosomal RNA genes to accurately profile mixed communities have shown that the extended amplicon read lengths allow coverage of more variable regions in a single read.

This results in more precise taxonomic assignment of organisms down to the genus and even species level, which is of particular importance for microbiome studies in clinical research.

Early access testing of the latest GS FLX+ software v2.9 was led by prominent researchers in the metagenomics field who also have optimized popular open source microbial community profiling tools QIIME and mothur for the latest long read data.

“The new software for the GS FLX+ System will enable researchers to obtain considerably longer sequence reads from 16S rRNA gene amplicons without sacrificing data quality,” explained Patrick Schloss, PhD, Assistant Professor at the University of Michigan and author of mothur.

Schloss continued, “This is a great advance for microbial ecologists since it will enable them to get better taxonomic classification of their data.”

In addition to advancing microbial profiling studies, the new GS FLX+ long amplicons will allow more comprehensive detection of genetic variations in human gene panels by spanning more introns and exons.

The long reads also improve haplotype phasing of more distantly linked variants, which is critical for genotyping of highly polymorphic regions of the genome such as the Human Leukocyte Antigen (HLA) gene.

Longer amplicon read lengths also significantly ease sequencing experimental design, workflow, and analysis by allowing optimal primer placement, the use of fewer amplicons to cover target regions, and direct transition of pre-existing Sanger amplicons to the GS FLX+ System.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Grants Roche’s Cancer Immunotherapy Tecentriq Accelerated Approval
Company has announced that the U.S. FDA has granted accelerated approval to Tecentriq® for the treatment of people with a specific type of advanced bladder cancer.
Friday, May 20, 2016
Tensha Therapeutics to be Acquired by Roche
Tensha Therapeutics, a privately-held company based in Cambridge, MA, has announced it will be acquired by Roche.
Tuesday, January 12, 2016
Roche Introduces Enhanced Whole Exome Sequencing Solution
The company has announced the launch of the SeqCap EZ MedExome Target Enrichment Kit1.
Wednesday, September 23, 2015
Roche to Acquire Kapa Biosystems
Acquisition to strengthen next-generation sequencing product offerings.
Friday, August 21, 2015
Roche's Investigational Immunotherapy Atezolizumab Shrank Tumours in People with Lung Cancer
Roche will discuss results with the U.S. FDA as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer.
Wednesday, August 19, 2015
Pivotal Phase II Study of Venetoclax Met Primary Endpoint
Venetoclax is a small molecule inhibitor of the BCL-2 protein, which potentially represents a new way of treating blood cancers.
Friday, August 14, 2015
Roche, Garvan Institute Epigenomic Partnership
Roche and the Garvan Institute of Medical Research today announce a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.
Wednesday, August 20, 2014
FDA Approves Roche’s Advanced Cervical Cancer Chemotherapy
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.
Monday, August 18, 2014
Roche to Acquire Seragon Pharmaceuticals
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer.
Wednesday, July 02, 2014
Roche Invests in Stratos Genomics
Investment by Roche will advance Stratos Genomics chemistry for nanopore sequencing.
Friday, June 27, 2014
Roche Recieves FDA Approval for Cervical Cancer Screening HPV Test
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older.
Friday, April 25, 2014
Roche, Oryzon Announce Epigenetics Collaboration
Collaboration spans research, development and commercialization of LSD1 inhibitors for oncology, haematology and non-malignant conditions.
Monday, April 07, 2014
FDA Recommends Roche's HPV Test as Primary Screening Tool
Test will assess risk of cervical cancer of women 25 years and older.
Thursday, March 13, 2014
Roche and Molecular Partners Enter into Alliance
Partnership will combine novel biologics with Roche drug-conjugate technology to develop new cancer treatments.
Wednesday, December 04, 2013
FDA Approves New Streamlined Workflow Option for Roche's Cobas HPV Test
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow.
Friday, June 28, 2013
Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!